It was a pleasure to meet with Prof. Stefan Schreiber (Department of Internal Medicine, University Hospital Schleswig-Holstein, Institute for Clinical Molecular Biology, Kiel, Germany)
to discuss the results from the maintenance phase of the True North study, investigating corticosteroid free remission in patients with ulcerative colitis treated with ozanimod.
The abstract entitled ‘142: CORTICOSTEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH OZANIMOD: RESULTS FROM THE MAINTENANCE PHASE OF TRUE NORTH’ was presented at DDW 2021, May 21-23.
- Could you give us a brief overview of the True North study and its findings? (0:11)
- Why is corticosteroid-free remission an important treatment goal in ulcerative colitis? (1:40)
- How were corticosteroid doses tapered in the maintenance phase of the True North study? (2:25)
- What were the results of the maintenance phase in terms of corticosteroid-free remission? (3:07)
- What are the implications of this finding, both for clinical practice and for future clinical trial design? (3:34)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, provention Bio, Protagonist, and Falk, outside the submitted DDW work.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
Share this Video
Related Videos In Inflammatory Bowel Disease
Detlef Schuppan, UEG 2021: Transglutaminase 2 Inhibitor in Celiac Disease
touchIMMUNOLOGY caught up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) to talk about the results for the phase 2 study investigating the oral transglutaminase 2 inhibitor, ZED1227, in patients with celiac disease. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN CELIAC PATIENTS UNDERGOING GLUTEN CHALLENGE’ was given at […]
Detlef Schuppan, UEG 2021: Advances in the Management of Celiac Disease
It was a pleasure to catch up with Prof. Detlef Schuppan (Mainz University Medical Center, Mainz, Germany) following his presentations at virtual UEG week to discuss the current unmet needs in the treatment of celiac disease and advances being made in its management. His presentation entitled ‘ORAL INHIBITOR OF TISSUE TRANSGLUTAMINASE PREVENTS MUCOSAL DAMAGE IN […]
Marc Ferrante, UEG 2021: Filgotinib SELECTION Study Results in Ulcerative Colitis
touchIMMUNOLOGY were delighted to speak with Dr Marc Ferrante (University Hospital Leuven, Leuven, Belgium) about the results from the phase 2B/3 study of filgotinib in patients with ulcerative colitis as well as the use of the Partial Mayo Clinical Score in measuring outcomes. His presentation entitled ‘EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!